Are you Dr. Sierra-Hoffman?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 36 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2710 Hospital Dr
#310
Victoria, TX 77901Phone+1 361-582-7925Fax+1 361-582-7926
Summary
- Dr. Miguel Sierra-Hoffman, MD is an infectious disease specialist in Victoria, Texas. He is currently licensed to practice medicine in Texas, Washington, and Alabama. He is affiliated with Citizens Medical Center, PAM Specialty Hospital of Victoria South, and DeTar Healthcare System.
Education & Training
USA HealthFellowship, Pulmonary Disease and Critical Care Medicine, 2004 - 2006
Texas A&M College of Medicine-Scott and White Medical Center (Temple)Fellowship, Infectious Disease, 2002 - 2004
Mercy Catholic Medical CenterResidency, Internal Medicine, 1999 - 2002
Universidad Nacional Autonoma de Honduras Class of 1991
Certifications & Licensure
WA State Medical License 2011 - 2026
TX State Medical License 2005 - 2025
AL State Medical License 2004 - 2006
PA State Medical License 1999 - 2002- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
- American Board of Internal Medicine Pulmonary Disease
Publications & Presentations
PubMed
- 7 citationsImpact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study.Estela Pineda, Jarmanjeet Singh, Miguel Vargas Pineda, Jose Garay Umanzor, Fernando Baires
Frontiers in Pharmacology. 2022-01-01 - 4 citationsImproved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community h...Kimberly Saddler, Jason Zhang, Jennifer Sul, Pruthvi Patel, Miriams T. Castro-Lainez
Plos One. 2021-03-18 - 26 citationsThe CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections.Mark Redell, Miguel Sierra-Hoffman, Maha Assi, Markian Bochan, David Chansolme
Open Forum Infectious Diseases. 2019-11-01
Press Mentions
Did Dismissals of Safe Outpatient Drugs Cause Needless Covid Deaths? Dissenting Doctors Say YesDecember 21st, 2021
